Company overview
RedShiftBio provides analytical instrumentation using Microfluidic Modulation Spectroscopy (MMS) and Liquid Chromatography (HaLCon) for protein and RNA analysis in drug development. Their Aurora TX and AQS3pro systems enable ultra-sensitive measurements of biomolecule structure, stability, aggregation, and concentration across wide ranges without dilution. These tools support bioprocessing, formulation, and characterization for therapeutic modalities including proteins and RNA.
RedShiftBio is listed in the NovaPharmaNews Supplier Hub as a Life Science Reagents partner serving United States & Americas. Core focus areas include redshiftbio, mms technology, protein analysis, rna characterization, biomolecule stability.
Industry categories: Life Science Reagents. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.redshiftbio.com
- Categories
- Life Science Reagents
- Markets served
- United States & Americas
- Keywords
- redshiftbio, mms technology, protein analysis, rna characterization, biomolecule stability
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What core technologies does RedShiftBio offer for biomolecule analysis?
- RedShiftBio offers Microfluidic Modulation Spectroscopy (MMS) for structure, stability, and aggregation analysis, and HaLCon Liquid Chromatography for real-time protein titer measurement in bioprocessing.
- What capabilities does the Aurora TX provide for RNA and protein analysis?
- Aurora TX uses MMS with thermal ramping for ultra-sensitive, automated measurements of RNA and protein structure, stability under temperature stress, and aggregation in native buffers across wide concentrations.
- What applications are supported by RedShiftBio instruments in pharma R&D?
- Instruments support drug discovery, development, and manufacturing by measuring critical quality attributes like structure, stability, titer, and aggregation for proteins, RNA, and other therapeutics.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
